Compare Msci Inc (MSCI) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Nuwellis Inc — how do they compare? Msci Inc trades at $554.53 (market cap $40.09B), while Nuwellis Inc trades at $0.8 (market cap $2.50M). The key difference: Msci Inc is far larger — about 16036× Nuwellis Inc's market cap, and Msci Inc pays a 1.49% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| MSCI | NUWE | |
|---|---|---|
Market Cap | $40.09B | $2.50M |
Sector | Financials | Technology |
52-Week High | $643.83 | $164.50 |
52-Week Low | $511.84 | $0.73 |
Enterprise Value | $46.25B | -$1.21M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent Q2 2026 earnings slightly missed expectations, but the company maintains robust profitability and a $2.05 dividend. Analyst consensus is bullish with a $728.14 price target, though technical indicators suggest near-term pressure with support at $545.
Outlook remains positive driven by high-margin recurring revenue and strategic acquisitions like First Street. Risks include elevated debt levels and market sensitivity. Institutional sentiment is strong with 73% buy ratings, positioning MSCI for long-term growth despite current technical weakness.
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
